Compare Regeneron Pharmaceuticals Inc (REGN) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs SYSCO Corporation — how do they compare? Regeneron Pharmaceuticals Inc trades at $747.44 (market cap $76.14B), while SYSCO Corporation trades at $78.2 (market cap $38.47B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and SYSCO Corporation pays the higher dividend (2.81%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and SYSCO Corporation for 77 Days on average.
| REGN | SYY | |
|---|---|---|
Market Cap | $76.14B | $38.47B |
Volume | 500,239 | 4,808,465 |
Sector | Health | Consumer Staples |
52-Week High | $852.03 | $91.16 |
52-Week Low | $557.73 | $69.30 |
Typical Hold Time | 107 Days | 77 Days |
Enterprise Value | $70.85B | $51.65B |
Dividend Yield | 0.51% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
Sysco Corporation (SYY) trades at $76.79, down 0.85% with a bearish technical outlook. The company shows solid revenue growth to $81.37B in 2025 but faces margin compression with net income margin at 2.08%. Recent developments include a $500M AI efficiency program and a $1.5B senior notes offering. Analyst consensus remains positive with 60% buy ratings and an $85.75 price target, representing 11.7% upside potential.
SYY offers value with a P/S ratio of 0.44x and dividend yield support, but faces execution risks on margin improvement and debt management. The stock trades below analyst targets, providing potential upside if the company delivers on its AI efficiency goals and maintains market leadership in food distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
